sustainability, [11] due to the combined effects of high insulin and androgen levels. Although oral contraceptives can effectively improve the menstrual cycle, protect the endometrium, and reduce the androgen levels, they have no effect on IR and other metabolic syndrome defects, and their long-term application contributes to glucose intolerance, abnormal lipid profiles, and cardiovascular disease. [12, 13] Metformin, a second-generation biguanide, is mainly used as an oral antihyperglycemic agent for treating type II diabetes mellitus and commonly used to improve PCOS-induced IR. It has been shown to improve PCOS-induced reproductive and metabolic defects. [14, 15] Many guidelines restrict its administration to PCOS patients with abnormal glucose metabolism. [10, [16] [17] [18] However, a recent study elucidated a strong correlation between metformin administration and increased ovulation rate in PCOS patients without abnormal glucose metabolism. [19] Notwithstanding, the mechanisms of its effects in PCOS are not fully elucidated. If metformin truly induces ovulation and improves metabolism, then it should be more widely used in women with PCOS. This study aimed at evaluating whether metformin has a similar effect on PCOS patients with or without IR.
methods

Study population
This study included 113 women who attended the PCOS Department in the reproductive endocrinology clinic of Obstetrics and Gynecology Hospital, Fudan University, from November 2015 to April 2018. To be included, they must be a current PCOS patient and not have been administered hormones or glycometabolism-regulating medication for 6 months. Patients with other hyperandrogenemia -causing diseases were excluded.
The Rotterdam criteria were used for PCOS diagnosis, which characterizes PCOS according to the following three key features: (1) oligo-or anovulation clinically manifested in menstrual cycle disturbance (the main condition); (2) clinical and/or biochemical signs of hyperandrogenism; and (3) the presence of polycystic ovaries in an ultrasound without other endocrine disorders. Two of these key features must be present before PCOS is diagnosed.
Patients were treated with metformin (1.5 g/d) from Shanghai Shiguibao in Shanghai, China, for 3 months.
Study methods
Classification of subgroups
HOMA-IR is a model of the relationship between glucose and insulin, which can be used to predict fasting steady-state glucose and insulin concentrations. The product of fasting glucose and fasting insulin is an index of hepatic IR, calculated as follows:
HOMA-IR = (FINS × FPG)/22.5
Where, FINS -fasting insulin (mU/L) and FPG -fasting plasma glucose (mmol/L).
Being the most practical value for clinical diagnoses of IR, HOMA-IR is not sufficiently predictive of the euglycemic clamp measures of insulin action, leading to no global consensus regarding the optimal indications for metformin. Age-, ethnicity-, and gender-specific differences in HOMA-IR levels reportedly exist, with women over 50 years having higher levels. [20] In this study, we used the 75% HOMA-IR cutoff value of 2.69, [21] widely used in PCOS research. [22, 23] Patients were allocated to either the IR group (if HOMA-IR was equal to or below 2.69) or the non-IR (NIR) group (if HOMA-IR was above 2.69) based on their HOMA-IR levels.
Research procedure
All characteristics were determined before and 3 months after metformin treatment. Physical examinations, including height, weight, and waist circumference, were performed by a doctor, according to the standard protocol. B-scan ultrasonography was used to find out whether the patient was in the early follicular phase and then blood was drawn. If the blood was not in the early follicular phase, blood was drawn again within 5 days of menstruation to check the related hormones. Oral glucose tolerance (OGTT) and insulin release tests were performed. Glucose levels were measured using a hexokinase enzymatic reference method. Insulin levels were measured using a radioimmunoassay kit (Coat A Count Insulin) from Diagnostic Product Corp. (Los Angeles, CA, USA). The endocrine characteristics included follicle-stimulating hormone, luteinizing hormone (LH), total testosterone (TT), sex hormone-binding globulin (SHBG), estradiol (E 2 ), progesterone (P), prolactin, dehydroepiandrosterone (DHEA-S), 17-hydroxyprogesterone (17a-OHP), and cortisol levels. The metabolic characteristics included total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL), apolipoprotein A (APO-A), APO-B, free fatty acid (FFA), and lipoprotein A levels. 
Statistical analyses
Statistical analyses were performed using the SPSS v22.0 software (SPSS Inc., Chicago, IL, USA). The Chi-square test was used to analyze differences in ovulation rate and improved menstrual cycle rate between the IR and NIR groups. One-way analysis of variance was used to analyze the differences in continuous variables (all parameters excluding ovulation rate and improved menstrual cycle rate) between the IR and NIR groups, and a paired t-test was used to analyze the differences between the pre-and post-treatment results.
resUlts
Baseline characteristics
Baseline characteristics are displayed in Table 1 . Patients in the IR group were elder than those in the NIR group, indicating that the disorder of glucose metabolism is aggravating with age in PCOS patients. BMI and waist circumference values were higher in the IR group than in the NIR group. The endocrine and metabolic characteristics of patients in the IR group were worse than those in the NIR group, indicating that endocrine health was closely related to metabolism. There were no differences in the TT and DHEA-S levels between the IR and NIR groups. However, SHBG levels significantly decreased in the IR group, leading to significant increase in FAI levels. This suggests that androgen activity increased in the IR group, which may have increased metabolic side effects [ Table 1 ].
Effects of metformin on menstrual cycle and ovulation
Seven patients lacked information on the efficacy of metformin in the menstrual cycle. Three months after metformin treatment, the menstrual cycle of 89 patients improved, and in 66 patients, ovulation was induced. In the IR group, metformin treatment resulted in menstrual cycle improvement and ovulation stimulation (mostly in the 1 st month of treatment) in 83.0% (39/47) and 63.8% (30/47) of the patients, respectively. In the NIR group, metformin treatment resulted in menstrual cycle improvement and ovulation stimulation in 84.7% (50/59) and 61.0% (36/59) of the patients, respectively. There were no statistically significant differences in the improved menstrual cycle (P = 0.178) and ovulation rates (P = 0.216) between the IR and NIR groups [ Figure 1 ], suggesting that metformin's therapeutic effect was not correlated with IR.
Effects of metformin on endocrine characteristics
In the IR group, LH and TT levels significantly decreased, whereas SHBG levels increased, leading to decreased FAI levels [ Table 2 ]. LH and FAI levels also significantly decreased in the NIR group, but SHBG levels increased, although not statistically significant.
Effects of metformin on glucose metabolism
The effect of metformin on glucose metabolism was determined using the OGTT and insulin release tests. Normally, the concentration of insulin peaks 30-60 min postglucose (75 g) administration. The peak concentration should be <5 times that before administration of glucose and should be reduced to normal level after 180 min. [16] In the IR group, metformin reduced glucose levels in each phase, especially at 0 and 180 min (P < 0.05). However, it had no significant (P ≥ 0.05) effects on the plasma glucose levels of each phase in the NIR group [ Figure 2 ], indicating metformin has no effect on the plasma glucose levels of patients with normal glucose metabolism.
Metformin inhibited insulin secretion in the IR group, with significant difference at 0, 60, 120, and 180 min (P < 0.05). However, it had no effect in the NIR group (P ≥ 0.05) [ Figure 3 ].
Effects of metformin on lipid metabolism
BMI and FAI are risk factors for metabolic syndrome and IR in women with PCOS, [17, 18] which positively correlates with HOMA-IR. The 3-month administration of metformin resulted in remarkably declined waist circumferences and BMIs in both the IR and NIR groups.
FFA, TG, TC, LDL, and APO-B are risk factors for cardiovascular disease, whereas HDL and APO-A can be regulated to prevent cardiovascular diseases. Metformin administration significantly decreased plasma TC and TG levels and increased APO-A levels in the IR group; however, it had no significant effect in the NIR group [ Table 3 ]. These results indicate that abnormal lipid metabolism was positively correlated with HOMA-IR, and metformin can significantly improve the metabolism of lipids in PCOS patients, which in a long run decreases the risk of CHD.
discUssion
Although metformin has been proven efficacious in PCOS patients, it is not universally indicated for these patients. The American Society for Reproductive Medicine recommends the use of metformin in women with PCOS and IGT who do not respond adequately to calorie restriction and lifestyle changes. [16] The American Endocrine Society recommends its use in women with a combination of PCOS, type 2 diabetes mellitus, or IGT and failed lifestyle modification treatment. [17] It has also been shown that metformin is efficacious only in a specific subgroup of women with PCOS with IR, menstrual disturbance, ovulation rates, and consecutive infertility problems. [18] These guidelines restrict its use to only a minority of PCOS patients. However, strong evidence exists on metformin's ability to increase the ovulation rate and ameliorate the metabolic defects in women with PCOS. [24] This study aimed at elucidating the efficacy of metformin in PCOS patients with normal clinical indices of insulin sensitivity. We found that 3-month metformin treatment significantly improved ovulation and menstrual cycle rates in both IR and NIR groups, suggesting that the efficacy of metformin treatment was not related to clinical indicators of IR. Metformin was also found to reduce LH and FAI levels in both groups, suggestive of the mechanisms of its effects on menstruation and ovulation. At the hypothalamic level, metformin acts via the AMPK pathway, essential for modulating the secretion of LH. [25] In addition, metformin inhibited the secretion of insulin in the IR group, but had no effect on that of the NIR group, which may result from its direct effect on ovarian steroidogenesis in PCOS patients without IR, independent of its effects on insulin sensitivity. [1] The focus of treatments for PCOS may switch from targeting early age reproductive disorders to targeting long-term metabolic and cardiovascular disorders. [6, 16, 26] The clinical features of PCOS are heterogeneous among races; 60%-70% of PCOS patients in America have hirsutism, while those in Eastern-Asia have milder hairy. [27] In China, hyperandrogenism is very common and the prevalence of metabolic disorders is extremely high. [24] The clinical heterogeneity of PCOS indicates the need for personalized treatment. In the present study, we found that PCOS patients with IR were elder. In addition, glucose and lipid metabolism were more impaired in the IR than the NIR group, indicating that IR and glycolipid metabolism disorders worsen with age. It is, therefore, essential to consider long-term health when selecting a treatment option. For instance, early control of IR is vital for the prevention of long-term complications. In addition, metformin to some extent improved the glucose and lipid metabolisms of PCOS patients in the IR group. However, due to the short period of metformin administration and young ages of patients in the NIR group, the effect of metformin on their glycolipid metabolism remained unclear.
This study has several advantages and limitations. One of its advantages is that the sample size is much larger than that of similar studies. [17, 28] Moreover, the results are relatively more reliable because all patients were recruited by the same doctor (using the same standards) and all blood samples were tested at the same hospital. The limitation of this study is that the vast majority of the patients are infertile, eager to conceive in the short term, which limits our long-term observation of the efficacy. Compared with half a year observation in other studies, the duration of metformin treatment in this study is only 3 months, which limits our long-term observation of metformin on reproductive endocrine and glycolipid metabolism. As the study is still under way, more results will be published in the future.
In conclusion, this study confirmed that metformin could improve the menstrual cycle and ovulation rate of PCOS patients regardless of IR. It also improves glycolipid metabolism. Metformin should be the first choice for the treatment of PCOS because this disease is often accompanied by cardiovascular and cerebrovascular metabolic diseases. However, this conclusion needs to be confirmed by long-term, double-blind, placebo-controlled studies.
